[{"id":"e1aa1af2-37cc-42c0-a2d8-53d46106cce9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03544723","created_at":"2021-01-18T17:27:13.078Z","updated_at":"2024-07-02T16:36:44.349Z","phase":"Phase 2","brief_title":"Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.","source_id_and_acronym":"NCT03544723","lead_sponsor":"MultiVir, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Ad-p53 gene therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2020-06-09"}]